SEC Filings
State Street Holds 4.6% Of Vera Therapeutics As Drug Launch Costs Climb
Vera's first partial commercial quarter brought $10.3 million in drug sales and a wider net loss.
Vera Therapeutics (VERA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Vera's first partial commercial quarter brought $10.3 million in drug sales and a wider net loss.
SEC Filings
TRUTAKNA's rollout brought approximately 700 patient start forms, while Vera seeks full FDA approval based on kidney-function data.
Earnings
Vera's commercial chief expects the demand share of sales to climb "much higher" in coming quarters, with a 50% covered-lives goal set for year-end.